Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003564priorityCriticalpatent/ECSP003564A/en
Publication of ECSP003564ApublicationCriticalpatent/ECSP003564A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención proporciona un procedimiento para tratar o prevenir la migraña que comprende administrar a un paciente en necesidad del mismo una cantidad eficaz de un antagonista selectivo del receptor iG1uR5 La presente invención proporciona además nuevos compuestos funcionales como antagonistas selectivos del receptor iG1uR5, asi como composiciones y formulaciones que comprenden dichos antagonistas selectivos del receptor iG1uR5.The present invention provides a method for treating or preventing migraine which comprises administering to an patient in need thereof an effective amount of a selective iG1uR5 receptor antagonist. The present invention further provides new functional compounds as selective iG1uR5 receptor antagonists, as well as compositions. and formulations comprising said selective iG1uR5 receptor antagonists.
ECSP0035642000-07-062000-07-06
SELECTIVE ANTAGONISTS OF THE RECEIVER OF iG1uR5 FOR THE TREATMENT OF MIGRAINE
ECSP003564A
(en)
USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER